Corporate Banner
Satellite Banner
Technology Networks Header
Thursday, October 23, 2014
Technology Networks
 
Register | Sign in
Home Page > Videos > Not happy with your ion chromatograph? Switch to Metrohm now and save!
  Videos

Return

Not happy with your ion chromatograph? Switch to Metrohm now and save!
Metrohm AG

Anyone thinking about exchanging his existing IC system should not wait any longer and switch to Metrohm now. Less need for expensive consumables, outstanding warranties and integral, fully automated sample preparation will benefit users with lower running costs, more efficiency, and highly dependable Swiss technology - for routine analysis and research alike. Investing in Metrohm ion chromatography means routine analysis with much less of expensive consumables such as syringe filters and filter caps required. Integral, fully automated sample preparation (inline dilution, inline calibration, inline dialysis) saves time and stress. The most important benefit in terms of saving money is the patented Metrohm anion suppressor module (MSM). Many users of ion chromatography may have grown used to costly replacements of the anion suppressor of their system every six months or even more frequently, not knowing that Metrohm ion chromatographs come with a 10 year suppressor warranty. This feature alone counts for thousands of US dollars saved over the lifetime of any Metrohm IC system. More and equally exclusive warranties such as a 10 year spare part warranty, 5 year software support, and a general 3 year instrument warranty contribute to a package that make Metrohm ion chromatography the better deal.

Request more information
Company product page



For access to this article, enter your email address to instantly recieve a Password Reset link.

Please enter your email address below:

Existing users please Sign In here. Don't have an account? Register Here for free access.

Don't have an account? | Register Here

Scientific News
Revalesio’s Drug Shows Promise in Treating Alzheimer’s
Multiple published research studies outline the potential for RNS60 to effectively treat Alzheimer’s disease by protecting neuronal function and restoring neuronal plasticity.
Getting Metabolism Right
Analysis of 89 models of metabolic processes finds flaws in 44 of them — but suggests corrections.
Persistent Pharmacokinetic Challenges to Pediatric Drug Development
Current knowledge of rational drug dose adjustments is limited, greater effort needs to be made to determine ontogenic factors that influence ADME.
‘Tissue Chip’ to Screen Neurological Toxins
UW-Madison team are developing a faster, more affordable way to screen for neural toxins.
Promise for Treatment of Pancreatic Cancer
Ultrasound microbubbles can improve tumor absorption of cancer drugs.
Animal Testing can Mislead Drug Discovery and Development
Several blockbuster drugs would not be on the market, if scientists had relied solely on drug-uptake in animal trials, according to new research.
Marijuana Compound May Offer Treatment for AD
Extremely low levels of the compound in marijuana known as delta-9-tetrahydrocannabinol, or THC, may slow or halt the progression of Alzheimer’s disease.
New Advances in the Pre-clinical Evaluation of Hepatitis B Therapies
Imperial College London to present first public HBV Data from CN Bio in vitro liver model.
ADME of Antibody-Maytansinoid Conjugates
Continued understanding of the ADME properties of ADCs entering clinical evaluations should provide additional insight into attributes that may be necessary for clinical success.
Epigenetic Regulation of ADME-Related Genes
The promise of epigenetic research is its potential to identify additional sources of inter individual variability in drug disposition and response.
Scroll Up
Scroll Down
Skyscraper Banner
Skyscraper Banner
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv